Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

HydrantID Selected by the State of California Department of Justice to Enable Identity Federation Service for Prescription Drug Monitoring Program (PDMP)

Posted on: 29 Sep 17

SALT LAKE CITY, Sept. 28, 2017 /PRNewswire/ -- HydrantID today announced it was selected by the State of California Department of Justice (CAL DOJ) to enable a Privacy-Ensured Identity Federation Service for the CAL DOJ Prescription Drug Monitoring Program called CURES (Controlled Substance Utilization Review and Evaluation System). HydrantID will utilize technology it has developed under a National Institute of Standards and Technology (NIST) pilot grant. The initial phase will be a "production pilot" to test the capabilities and establish the benefits of federated authentication for users of the program. The goal is to facilitate and streamline secure access by authorized health care providers to the California DOJ CURES Prescription Drug Monitoring Program, utilizing their previously established hospital issued credentials. 

California prescribers and pharmacists are required by law to register to use CURES to check patient activity with respect to schedule II, III, IV controlled substance prescriptions dispensed in California. Doing so serves the public health, regulatory oversight agencies, and law enforcement. The information in CURES may only be accessed by authorized users, which requires authentication credentials be issued under strict processes, which are costly, inconvenient, and time-consuming.

"Streamlining the CURES authentication process through a Privacy-Enforced Identity Federation eliminates the need for caregivers to manage and remember yet another credential and, in some instances, offer a single sign-on experience from Electronic Medical Record systems," said Mike Small, Program Manager of the California Department of Justice CURES program.

CURES receives about 1 million prescription reports each week. Over 23,000 deaths occur each year due to Prescription Painkiller Overdose. The CURES database allows the medical community to monitor patient prescriptions more accurately. Utilizing a secure identity federation, will allow providers to sign-on to CURES with their established hospital issued credentials eliminating the need to re-authenticate.

"We are pleased to be assisting the CAL DOJ with its efforts to combat opioid abuse by enabling simple and secure access for health care providers to information they need in their efforts to save lives," said Trell Rohovit, CEO of HydrantID.

About the California Department of Justice CURES Program

CURES 2.0 (Controlled Substance Utilization Review and Evaluation System) is a database of Schedule II, III and IV controlled substance prescriptions dispensed in California serving the public health, regulatory oversight agencies, and law enforcement. CURES 2.0 is committed to the reduction of prescription drug abuse and diversion without affecting legitimate medical practice or patient care.

For more information, visit

About HydrantID

HydrantID provides security infrastructure as a service. Our primary focus is on delivering encryption and advanced authentication solutions to help companies secure access to data, machines, networks, IoT devices, and e-commerce transactions. HydrantID focuses on helping companies achieve industry best practices related to authentication and encryption while reducing operating complexity and costs. HydrantID's cloud-based, SaaS platform allows organizations to obtain advanced authentication and encryption services on-demand, in real-time. An industry-leading fixed-price subscription model eliminates financial and operational barriers that start-ups, and Fortune 500 companies alike, face in creating strong security practices.

For more information, visit

Contact Information:
Andrea Westlake 

Editor's Details

Mike Wood

Last updated on: 29/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.